Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Accumulated Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other Accumulated Expenses for 14 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses changed N/A to $3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.8 million for FY2025, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $3.8 million at Cytokinetics, up from $2.0 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $14.8 million in Q1 2024, with the low at $1.1 million in Q4 2022.
  • Average Other Accumulated Expenses over 5 years is $6.9 million, with a median of $6.4 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 840.25% in 2023, then tumbled 81.39% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $1.5 million in 2021, then fell by 27.08% to $1.1 million in 2022, then surged by 840.25% to $10.6 million in 2023, then grew by 1.19% to $10.7 million in 2024, then crashed by 64.13% to $3.8 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $3.8 million, $2.0 million, and $8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.